One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: A prospective study of 15 030 pregnancies

Ultrasound in Obstetrics and Gynecology

Volumn 20, Issue 3, 2002, Pages 219-225

  Bindra, R ^a   Heath, V ^a   Liao, A ^a   Spencer, K ^b   Nicolaides, K H ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b HAROLD WOOD HOSPITAL   (United Kingdom)

Author keywords

hCG; Down syndrome; First trimester; Nuchal translucency; PAPP A; Screening

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; ARTICLE; BLOOD CHEMISTRY; CHROMOSOME DISORDER; CONTROLLED STUDY; CROWN RUMP LENGTH; DIAGNOSTIC ERROR; FEMALE; FETUS; FETUS ECHOGRAPHY; FOLLOW UP; GENETIC COUNSELING; GENETIC SCREENING; GESTATIONAL AGE; HORMONE BLOOD LEVEL; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MATERNAL AGE; OUTPATIENT DEPARTMENT; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; THICKNESS; TRISOMY 21;

ADULT; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DOWN SYNDROME; FEMALE; FOLLOW-UP STUDIES; GESTATIONAL AGE; HUMANS; MASS SCREENING; MATERNAL AGE; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY, HIGH-RISK; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 0036378243     PISSN: 09607692     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0705.2002.00808.x     Document Type: Article

References (30)

1. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free β-human chorionic gonadotropin and pregnancy associated plasma protein-A. Ultrasound Obstet Gynecol 1999; 13: 231-7
2. Snijders RJM, Noble P, Sebire N, Souka A, Nicolaides KH. UK multi-centre project on assessment of risk for trisomy 21 by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Lancet 1999; 18: 519-21
3. Wald NJ, Kennard A, Hackshaw A, McGuire A. Antenatal screening for Down's syndrome. Health Technol Assess 1998; 2: 1-112
4. Spencer K, Spencer CE, Power M, Moakes A, Nicolaides KH. One stop clinic for assessment of risk for fetal anomalies; a report of the first year of prospective screening for chromosomal anomalies in the first trimester. Br J Obstet Gynaecol 2000; 107: 1271-5
5. Levett LJ, Liddle S, Meredith R. A large-scale evaluation of amnio-PCR for the rapid prenatal diagnosis of fetal trisomy. Ultrasound Obstet Gynecol 2001; 17: 115-8
6. Snijders RJM, Sundberg K, Holzgreve W, Henry G, Nicolaides KH. Maternal age and gestation specific risk for trisomy 21. Ultrasound Obstet Gynecol 1999; 13: 167-70
7. Hecht CA, Hook EB. The imprecision in rates of Down syndrome by 1-year matenal age intervals: a critical analysis of rates used in biochemical screening. Prenat Diagn 1994; 14: 729-38
8. Kornman LH, Morssink LP, Beekhuis JR, DeWolf BTHM, Heringa MP, Mantingh A. Nuchal translucency cannot be used as a screening test for chromosomal abnormalities in the first trimester of pregnancy in a routine ultrasound practice. Prenat Diagn 1996; 16: 797-805
9. Bower S, Chitty L, Bewley S, Roberts L, Clark T, Fisk NM, Maxwell D, Rodeck CH. First trimester nuchal translucency screening of the general population: data from three centres [Abstract]. Presented at: The 27th British Congress of Obstetrics and Gynaecology, Dublin, 1995. London: Royal College of Obstetrics and Gynaecology 1995
10. Roberts LJ, Bewley S, Mackinson AM, Rodeck CH. First trimester fetal nuchal translucency: Problems with screening the general population 1. Br J Obstet Gynaecol 1995; 102: 381-5
11. Monni G, Zoppi MA, Ibba RM, Floris M. Results of measurement of nuchal translucency before and after training. Lancet 1997; 350: 1631
12. Pandya PP, Goldberg H, Walton B, Riddle A, Shelley S, Snijders RJM, Nicolaides KH. The implementation of first-trimester scanning at 10-13 weeks' gestation and the measurement of fetal nuchal translucency thickness in two maternity units. Ultrasound Obstet Gynecol 1995; 5: 20-5
13. Szabo J, Gellen J, Szemere G. First-trimester ultrasound screening for fetal aneuploidies in women over 35 and under 35 years of age. Ultrasound Obstet Gynecol 1995; 5: 161-3
14. Taipale P, Hiilesmaa V, Salonen R, Ylostalo P. Increased nuchal translucency as a marker for fetal chromosomal defects. N Engl J Med 1997; 337: 1654-8
15. Hafner E, Schuchter K, Liebhart E, Philipp K. Results of routine fetal nuchal translucency measurement at 10-13 weeks in 4 233 unselected pregnant women. Prenat Diagn 1998; 18: 29-34
16. Pajkrt E, van Lith JMM, Mol BWJ, Bleker OP, Bilardo CM. Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population. Ultrasound Obstet Gynecol 1998; 12: 163-9
17. Economides DL, Whitlow BJ, Kadir R, Lazanakis M, Verdin SM. First trimester sonographic detection of chromosomal abnormalities in an unselected population. Br J Obstet Gynaecol 1998; 105: 58-62
18. Schwarzler P, Carvalho JS, Senat MV, Masroor T, Campbell S, Ville Y. Screening for fetal aneuploidies and fetal cardiac abnormalities by nuchal translucency thickness measurement at 10-14 weeks of gestation as part of routine antenatal care in an unselected population. Br J Obstet Gynaecol 1999; 106: 1029-34
19. Theodoropoulos P, Lolis D, Papageorgiou C, Papaioannou S, Plachouras N, Makrydimas G. Evaluation of first-trimester screening by fetal nuchal translucency and maternal age. Prenat Diagn 1998; 18: 133-7
20. Zoppi MA, Ibba RM, Floris M, Monni G. Fetal nuchal translucency screening in 12 495 pregnancies in Sardinia. Ultrasound Obstet Gynecol 2001; 18: 649-51
21. Gasiorek-Wiens A, Tercanli S, Kozlowski P, Kossakiewicz A, Minderer S, Meyberg H, Kamin G, Germer U, Bielicki M, Hackeloer BJ, Sarlay D, Kuhn P, Klapp J, Bahlmann F, Pruggmayer M, Schneider KTM, Seefried W, Fritzer E, von Kaisenberg CS. Screening for trisomy 21 by fetal nuchal translucency and maternal age: a multicenter project in Germany, Austria and Switzerland. Ultrasound Obstet Gynecol 2001; 18: 645-8
22. Brizot ML, Carvalho MHB, Liao AW, Reis SV, Armbruster-Moraes E, Zugaib M. First-trimester screening for chromosomal abnormalities by fetal nuchal translucency in a Brazilian population. Ultrasound Obstet Gynecol 2001; 18: 652-5
23. Audibert F, Dommergues M, Benattar C, Taieb J, Thalabard JC, Frydman R. Screening for Down syndrome using first-trimester ultrasound and second-trimester maternal serum markers in a low-risk population: a prospective longitudinal study. Ultrasound Obstet Gynecol 2001; 18: 26-31
24. Wayda K, Kereszturi A, Orvos H, Horvath E, Pal A, Kovacs L, Szabo J. Four years experience of first-trimester nuchal translucency screening for fetal aneuploidies with increasing regional availability. Acta Obstet Gynecol Scand 2001; 80: 1104-9
25. Spencer K. Evaluation of effect of analytical imprecision in maternal serum screening for Down's syndrome. Ann Clin Biochem 2001; 38: 413-4
26. Seth J, Sturgeon CM, Ellis AR, Al-Sadie R, Logan M. UKNEQAS for peptide hormones and related substances, Annual Review 2000: Edinburgh 2001, pp. 67-9
27. Souka AP, Krampl E, Bakalis S, Heath V, Nicolaides KH. Outcome of pregnancy in chromosomally normal fetuses with increased nuchal translucency in the first trimester. Ultrasound Obstet Gynecol 2001; 18: 9-17
28. Souka AP, Nicolaides KH. Diagnosis of fetal abnormalities at the 10-14-week scan. Ultrasound Obstet Gynecol 1997; 10: 429-42
29. Nicolaides KH. Screening for fetal chromosomal abnormalities: need to change the rules. Ultrasound Obstet Gynecol 1994; 4: 353-4
30. Cuckle H. Time for a total shift to first trimester screening for Down's Syndrome. Lancet 2001; 358: 1658-9